Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))

J. Vansteenkiste, T. Reungwetwattana, K. Nakagawa, B. C. Cho, M. A.Cobo Dols, E. K. Cho, A. Bertolini, S. Bohnet, C. Zhou, K. H. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, A. P. Brown, Y. Rukazenkov, S. Ramalingam

Research output: Contribution to journalComment/debatepeer-review

11 Citations (Scopus)

Abstract

Ann Oncol 2017; 28: x7 (doi: 10.1093/annonc/mdx729) In the abstract LBA5, the names of authors A. Bertolini and Y. Rukazenkov were originally misspelt. They have now been corrected.

Original languageEnglish
Pages (from-to)x196
JournalAnnals of Oncology
Volume28
DOIs
Publication statusPublished - 2017 Nov

Bibliographical note

Publisher Copyright:
© 2018 THE AUTHORS

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Erratum: CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (Annals of Oncology (2017) 28(S10) (x183), (S0923753419565462), (10.1093/annonc/mdx729))'. Together they form a unique fingerprint.

Cite this